# Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

> **NCT00318890** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 48 (actual)

## Conditions studied

- Cancer of Head and Neck
- Head Cancer
- Head and Neck Cancer
- Neck Cancer
- Neck Neoplasms

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **PROCEDURE:** Radiotherapy
- **DRUG:** Amifostine

## Key facts

- **NCT ID:** NCT00318890
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2007-04
- **Final completion:** 2007-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318890, "Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00318890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*